Cargando…
Pulmonary complications in hematopoietic SCT: a prospective study
Pulmonary complications are common and often lethal in hematopoietic SCT recipients. The objective of this prospective interventional study was to evaluate the etiology, diagnostic procedures, risk factors and outcome of pulmonary complications in a cohort of hematopoietic SCT recipients followed up...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094728/ https://www.ncbi.nlm.nih.gov/pubmed/25046219 http://dx.doi.org/10.1038/bmt.2014.151 |
_version_ | 1783510529754529792 |
---|---|
author | Lucena, C M Torres, A Rovira, M Marcos, M A de la Bellacasa, J P Sánchez, M Domingo, R Gabarrus, A Mensa, J Agustí, C |
author_facet | Lucena, C M Torres, A Rovira, M Marcos, M A de la Bellacasa, J P Sánchez, M Domingo, R Gabarrus, A Mensa, J Agustí, C |
author_sort | Lucena, C M |
collection | PubMed |
description | Pulmonary complications are common and often lethal in hematopoietic SCT recipients. The objective of this prospective interventional study was to evaluate the etiology, diagnostic procedures, risk factors and outcome of pulmonary complications in a cohort of hematopoietic SCT recipients followed up for 1 year. For patients suffering from a pulmonary complication, a diagnostic algorithm that included non-invasive and bronchoscopic procedures was performed. We identified 73 pulmonary complications in 169 patients: 50 (68%) were pneumonias; 21 (29%) were non-infectious complications and 2 (3%) were undiagnosed. Viruses (particularly Rhinovirus) and bacteria (particularly P. aeruginosa) (28 and 26%, respectively) were the most common causes of pneumonia. A specific diagnosis was obtained in 83% of the cases. A non-invasive test gave a specific diagnosis in 59% of the episodes. The diagnostic yield of bronchoscopy was 67 and 78% in pulmonary infections. Early bronchoscopy (⩽5 days) had higher diagnostic yield than late bronchoscopy (78 vs 23%; P=0.02) for pulmonary infections. Overall mortality was 22 and 32% of all fatalities were due to pulmonary complications. Pulmonary complications are common and constitute an independent risk factor for mortality, stressing the importance of an appropriate clinical management. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/bmt.2014.151) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7094728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70947282020-03-26 Pulmonary complications in hematopoietic SCT: a prospective study Lucena, C M Torres, A Rovira, M Marcos, M A de la Bellacasa, J P Sánchez, M Domingo, R Gabarrus, A Mensa, J Agustí, C Bone Marrow Transplant Article Pulmonary complications are common and often lethal in hematopoietic SCT recipients. The objective of this prospective interventional study was to evaluate the etiology, diagnostic procedures, risk factors and outcome of pulmonary complications in a cohort of hematopoietic SCT recipients followed up for 1 year. For patients suffering from a pulmonary complication, a diagnostic algorithm that included non-invasive and bronchoscopic procedures was performed. We identified 73 pulmonary complications in 169 patients: 50 (68%) were pneumonias; 21 (29%) were non-infectious complications and 2 (3%) were undiagnosed. Viruses (particularly Rhinovirus) and bacteria (particularly P. aeruginosa) (28 and 26%, respectively) were the most common causes of pneumonia. A specific diagnosis was obtained in 83% of the cases. A non-invasive test gave a specific diagnosis in 59% of the episodes. The diagnostic yield of bronchoscopy was 67 and 78% in pulmonary infections. Early bronchoscopy (⩽5 days) had higher diagnostic yield than late bronchoscopy (78 vs 23%; P=0.02) for pulmonary infections. Overall mortality was 22 and 32% of all fatalities were due to pulmonary complications. Pulmonary complications are common and constitute an independent risk factor for mortality, stressing the importance of an appropriate clinical management. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/bmt.2014.151) contains supplementary material, which is available to authorized users. Nature Publishing Group UK 2014-07-21 2014 /pmc/articles/PMC7094728/ /pubmed/25046219 http://dx.doi.org/10.1038/bmt.2014.151 Text en © Macmillan Publishers Limited 2014 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Lucena, C M Torres, A Rovira, M Marcos, M A de la Bellacasa, J P Sánchez, M Domingo, R Gabarrus, A Mensa, J Agustí, C Pulmonary complications in hematopoietic SCT: a prospective study |
title | Pulmonary complications in hematopoietic SCT: a prospective study |
title_full | Pulmonary complications in hematopoietic SCT: a prospective study |
title_fullStr | Pulmonary complications in hematopoietic SCT: a prospective study |
title_full_unstemmed | Pulmonary complications in hematopoietic SCT: a prospective study |
title_short | Pulmonary complications in hematopoietic SCT: a prospective study |
title_sort | pulmonary complications in hematopoietic sct: a prospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094728/ https://www.ncbi.nlm.nih.gov/pubmed/25046219 http://dx.doi.org/10.1038/bmt.2014.151 |
work_keys_str_mv | AT lucenacm pulmonarycomplicationsinhematopoieticsctaprospectivestudy AT torresa pulmonarycomplicationsinhematopoieticsctaprospectivestudy AT roviram pulmonarycomplicationsinhematopoieticsctaprospectivestudy AT marcosma pulmonarycomplicationsinhematopoieticsctaprospectivestudy AT delabellacasajp pulmonarycomplicationsinhematopoieticsctaprospectivestudy AT sanchezm pulmonarycomplicationsinhematopoieticsctaprospectivestudy AT domingor pulmonarycomplicationsinhematopoieticsctaprospectivestudy AT gabarrusa pulmonarycomplicationsinhematopoieticsctaprospectivestudy AT mensaj pulmonarycomplicationsinhematopoieticsctaprospectivestudy AT agustic pulmonarycomplicationsinhematopoieticsctaprospectivestudy |